Literature DB >> 15341519

Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system.

Juan E Ferrario1, Irene R E Taravini, Sophie Mourlevat, Andrea Stefano, Marina A Delfino, Rita Raisman-Vozari, M Gustavo Murer, Merle Ruberg, Oscar Gershanik.   

Abstract

Levodopa, the major treatment for patients with Parkinson's disease, has been shown to induce a variety of compensatory effects, including facilitation of sprouting by dopaminergic neurons, in experimental animals with lesions leading to denervation of the striatum. To better understand the cellular and molecular environment where most of these compensatory changes take place, in particular elements that might contribute to the recovery of dopaminergic innervation, we have constructed a differential expression library enriched in transcripts from the striata of rats with lesions of the medial forebrain bundle treated with levodopa for 6 months. We have used this library to screen an expression array of rat genes representing the major cell functions, and have identified several that are involved in neurotrophic mechanisms and plasticity. We have confirmed the differential expression of selected transcripts by non-radioactive in situ hybridization, and report that the growth factor pleiotrophin, myelin basic protein and calmodulin are overexpressed in the denervated striatum of levodopa-treated rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341519     DOI: 10.1111/j.1471-4159.2004.02595.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

1.  Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Authors:  Sara E Gombash; Jack W Lipton; Timothy J Collier; Lalitha Madhavan; Kathy Steece-Collier; Allyson Cole-Strauss; Brian T Terpstra; Anne L Spieles-Engemann; Brian F Daley; Susan L Wohlgenant; Valerie B Thompson; Fredric P Manfredsson; Ronald J Mandel; Caryl E Sortwell
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 3.  Present and future drug treatment for Parkinson's disease.

Authors:  A H V Schapira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

Review 4.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

5.  Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries.

Authors:  M M Lewis; C G Slagle; A B Smith; Y Truong; P Bai; M J McKeown; R B Mailman; A Belger; X Huang
Journal:  Neuroscience       Date:  2007-05-17       Impact factor: 3.590

6.  Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area.

Authors:  Daniel García-Pérez; M Luisa Laorden; M Victoria Milanés
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

7.  Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats.

Authors:  Irene Re Taravini; Mariela Chertoff; Eduardo G Cafferata; José Courty; Mario G Murer; Fernando J Pitossi; Oscar S Gershanik
Journal:  Mol Neurodegener       Date:  2011-06-07       Impact factor: 14.195

Review 8.  Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus.

Authors:  Celia González-Castillo; Daniel Ortuño-Sahagún; Carolina Guzmán-Brambila; Mercè Pallàs; Argelia Esperanza Rojas-Mayorquín
Journal:  Front Cell Neurosci       Date:  2015-01-08       Impact factor: 5.505

9.  Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study.

Authors:  Douglas C Dean; Jitka Sojkova; Samuel Hurley; Steven Kecskemeti; Ozioma Okonkwo; Barbara B Bendlin; Frances Theisen; Sterling C Johnson; Andrew L Alexander; Catherine L Gallagher
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

10.  Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.

Authors:  Sylviane Lortet; Emilie Lacombe; Nicolas Boulanger; Pascal Rihet; Catherine Nguyen; Lydia Kerkerian-Le Goff; Pascal Salin
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.